January 15, 2016
School’s Division of Translational Radiation Science to Lead Efforts in Radiation Mitigation and Protection to Benefit National Security and Patients
University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).
Under the leadership of Zeljko Vujaskovic, MD, PhD, Professor of Radiation Oncology and Director of the Department’s Division of Translational Radiation Science (DTRS), UM SOM researchers will work with BARDA to support the development of radiologic and nuclear countermeasures. This Indefinite Delivery/ Indefinite Quantity (IDIQ) contract (HHSO100201500009I) is part of a broader effort to enhance national preparedness for radiation accidents and emergencies.
“Our Division is in a unique position to lead in medical countermeasures research,” said Dr. Vujaskovic. “We have extensive experience with experimental models, 30,000 square feet of dedicated space for radiation research, and collaborative expertise from across the broadest spectrum of countermeasure investigations, which allow us to rapidly configure and implement solutions-oriented approaches to even the most difficult challenges.”
DTRS was launched in 2012, when Dr. Vujaskovic joined UM SOM from Duke University. He is an internationally recognized physician scientist whose work over the last three decades has focused on elucidating the mechanisms associated with radiation normal tissue injury, identifying potential biomarkers predicting individual risk for injury, and developing novel therapeutic interventions/strategies to prevent, mitigate, or treat radiation injury.
DTRS already partners with government, pharmaceutical, biotechnology, and medical device entities on a range of medical and radiation oncology, radiation biology/physics,and biodefense projects. Earlier in 2015, research by DTRS faculty and staff led to FDA approval of the first drug to treat the deleterious effects of radiation exposure following a nuclear incident based on efficacy data generated in animal models. Animal models are especially important in preparing for radiation emergencies, because the efficacy of most experimental treatments cannot be tested in humans. The GLP (Good Laboratory Practice)-compliant testing facility within DTRS has expertise with different experimental models, along with one of the nation’s most well equipped suites of technologies supporting radiation research. The work with BARDA will include multiple individual projects that draw on changing configurations of DTRS experts, instrumentation, and specialized resources, as well as on collaborations with other UM SOM and University of Maryland, Baltimore investigators.
According to Dr. Regine, medical countermeasure studies have the potential to provide knowledge that can improve treatment of patients undergoing radiation treatment for a variety of cancers. “Our strong and well-integrated bench-to-bedside continuum within the Department of Radiation Oncology allows us to move new insights into the biology of radiation injury and recovery very quickly to clinical applications for patients undergoing therapy for cancer treatment,” said Dr. Regine, who also holds the Isadore & Fannie Schneider Foxman Endowed Professorship. “We are honored to have Dr. Vujaskovic and his team work with BARDA in this effort. The agency understands that discoveries that are crucial in meeting radiation emergencies can also have extraordinary potential for later development in routine clinical use.” He noted that 60 percent of all diagnosed cancer patients receive radiation therapy as part of their treatment.
Over the past 40 years, the UM SOM’s Department of Radiation Oncology has been a leader in conducting large-scale research in radiation science, and in many ways has helped define the field. Now, the Division of Translational Radiation Sciences is building on that foundation, by continuing to conduct both small and large animal efficacy studies and further developing the capability to use a range of supportive care – from minimal population-based to individual, ICU-type care.
“We are very excited to continue this critical research with BARDA,” said Dean E. Albert Reece, MD, PhD, MBA, who is also Vice President of Medical Affairs, the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor at UM SOM. “In particular, our ability to utilize our GLP-testing facility for medical countermeasures, oncology drugs based on tumor models and normal tissue complications from radiation treatment makes us a true leader in the field of translational radiation science.”
Task Orders awarded under the contract will be funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500009I.
About the University of Maryland School of Medicine
The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States, continuing today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic, and clinically-based education. With 43 academic departments, centers, and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S., with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development, and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation but also has a global presence, with research and treatment facilities in more than 35 countries around the world. http://medschool.umaryland.edu/
About the Division of Translational Radiation Sciences
The Division of Translational Radiation Sciences (DTRS), a part of the Department of Radiation Oncology at the University of Maryland School of Medicine, was established to accelerate the discovery and clinical implementation of new therapeutic strategies to improve tumor response in clinical radiotherapy, minimize post-radiation therapy complications, and mitigate/treat the life-threatening health effects of a radioactive or nuclear agent brought on by a nuclear/terrorist incident. DTRS offers a multidisciplinary approach to address the knowledge gaps in radiation oncology, biology, and physics to facilitate discovery and innovation. This is accomplished through building on the experience and multidisciplinary expertise of our faculty members within the Division. The Division provides a comprehensive set of services to the U.S. government, pharmaceutical, biotechnology, and medical device companies in the areas of medical and radiation oncology, radiation biology/physics, and biodefense.
Contact
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
(410) 706-5260
Related stories
Monday, February 26, 2024
UM School of Medicine Awarded $3.5 Million in Federal Funding to Expand Medical Countermeasures Program
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that UMSOM faculty scientists have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for the federal agency’s Radiation Nuclear Animal Model Development program. The $3.5 million award that Erika Davies, PhD, Assistant Professor of Radiation Oncology, received to develop Acute Radiation Syndrome Animal Models, has a $16 million potential total. The Division of Translational Radiation Sciences (DTRS), within the Department of Radiation Oncology, will support this project.
Thursday, March 09, 2023
Leading Physician-Scientist Dr. William F. Regine Named Senior Associate Dean for Clinical Affairs at UM School of Medicine and President of UM Faculty Physicians, Inc.
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD announced today that William F. Regine, MD, FACR, FASTRO, FACRO has been appointed to the executive role of Senior Associate Dean for Clinical Affairs at the University of Maryland School of Medicine (SOM), effective immediately.
Tuesday, December 07, 2021
UM School of Medicine's Department of Radiation Oncology Announces that Preeminent Scientist, Dr. Zeljko Vujaskovic, will Transition to New Role in the Department
University of Maryland School of Medicine (UMSOM) Radiation Oncology Department Chair William F. Regine, MD, FACR, FACRO, announced today that Zeljko Vujaskovic, MD, PhD, Professor and Vice Chair for Research in the Department of Radiation Oncology, will transition from his current faculty position to a new role in the Department, effective December 3, 2021.
Tuesday, August 24, 2021
Three UMSOM Faculty Members Recognized as 2021 Maryland Daily Record Health Care Heroes
The Maryland Daily Record has honored three leading faculty members at the University of Maryland School of Medicine (UMSOM) with its 2021 Health Care Heroes Awards. The award recognizes those who have provided exceptional service and made significant impacts on the quality of health care in the State of Maryland this year. An outside panel of health care experts selected the winners.
Tuesday, November 17, 2020
UMSOM's Department of Radiation Oncology Announces New Endowed Professorship and Senior Leadership Appointments in the Department
University of Maryland School of Medicine (UMSOM) Department of Radiation Oncology Chair William F. Regine, MD, FACR, FACRO, along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that three prominent faculty members in the Department of Radiation Oncology will be promoted into leading department positions that recognize their outstanding academic scholarship and success.
Friday, October 11, 2019
New Treatment Combination Could Work Against Broader Array of Cancer Cells, Study Finds
In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, published this week in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are currently approved by the FDA to treat only a limited group of breast and ovarian cancers associated with BRCA gene mutations.
Wednesday, July 31, 2019
Inconsistent Reporting of Methodologies Makes Most Radiation Biology Studies Impossible to Replicate
Nearly 80 percent of radiation oncology studies funded by the National Institutes of Health involve investigating the effects that radiation has on tumor cells and healthy tissue in pre-clinical settings, such as experiments done in cell cultures or mice. A majority of these radiation biology studies, however, have serious flaws in how their irradiation methodology is described, which makes them very difficult to replicate, according to a new finding from the University of Maryland School of Medicine (UMSOM).
Tuesday, February 19, 2019
Dr. Robert C. Miller, National Leader in Radiation Oncology, Named New Medical Director of Maryland Proton Treatment Center
William F. Regine, MD, FACR, FACRO, The Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Robert C. Miller, MD, MBA, FASTRO a nationally-recognized radiation oncologist who currently serves as Vice Chair in the Department of Radiation Oncology at the Mayo Clinic, has been named Professor in the UMSOM Department of Radiation Oncology and Medical Director of the Maryland Proton Treatment Center (MPTC). He will begin his new position in April 2019.
Monday, October 29, 2018
UMSOM Honors Breast Cancer Awareness Month, Our Research Continues Toward Combating this Disease
October is Breast Cancer Awareness Month, and researchers at the University of Maryland School of Medicine (UMSOM) continue in their work to help combat this disease that impacts more than 315,000 women in the U.S. each year.
Monday, October 08, 2018
High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy
The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.
Monday, September 24, 2018
University of Maryland School of Medicine Researchers to Present Original Research at Key Radiation Conference
The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.
Monday, May 14, 2018
Gov. Larry Hogan Recognizes Achievements of Sally B. Cheston, MD, of Central Maryland Radiation Oncology Center
Maryland Gov. Larry Hogan today recognized Sally B. Cheston, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine (UMSOM), for her efforts to bring the “latest state-of-the-art medicine” to Howard County as a leader of the Central Maryland Radiation Oncology Center (CMRO).
Friday, December 22, 2017
First Stereotactic Radiation Therapy System Designed To Treat Early Stage Breast Cancer Receives FDA Clearance
The GammaPod ™ – a first-of-its kind stereotactic radiotherapy system to treat early stage breast cancer – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), paving the way for the manufacturer to bring the system to market for the treatment of breast cancer patients.
Wednesday, October 18, 2017
University of Maryland School of Medicine Scientists Set to Begin Critical Radiation Countermeasures Research
University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that UM SOM researchers have been awarded a contract worth up to $9.7 million over three years, from the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to study new ways to treat radiation-induced bleeding disorders. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
Thursday, October 27, 2016
Dr. William F. Regine is Awarded 2016 Entrepreneur of the Year From the University of Maryland, Baltimore
William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor in Radiation Oncology at the University of Maryland School of Medicine (UM SOM) and Executive Director of the Maryland Proton Treatment Center (MPTC) has been awarded the 2016 Entrepreneur of the Year from the University of Maryland, Baltimore (UMB).
Thursday, July 14, 2016
Dr. Charles B. Simone, II Appointed Medical Director of the Maryland Proton Treatment Center
William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Foxman Schneider Endowed Chairman and Professor of Radiation Oncology at the University of Maryland School of Medicine (UM SOM) and the Executive Director of the Maryland Proton Treatment Center (MPTC), along with UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Charles B. Simone, II, MD, a nationally-recognized expert in proton therapy at the University of Pennsylvania, has been named the new Medical Director of the MPTC. Dr. Simone will also be appointed Associate Professor in the UM SOM Department of Radiation Oncology and will begin in his new position in November 2016.
Wednesday, April 13, 2016
Leading Physician-Scientist at University of Maryland School of Medicine Receives Award for Innovative Work in Thermal Treatment for Cancer
Zeljko Vujaskovic, MD, PhD, an internationally recognized physician scientist and Professor of Radiation Oncology at the University of Maryland School of Medicine (UM SOM), will receive the 2016 J. Eugene Robinson Award at the annual Society for Thermal Medicine Meeting in New Orleans, held April 11 to 15. Dr. Vujaskovic, who is also Director of the Division of Translational Radiation Sciences in the UM SOM Department of Radiation Oncology, and Director of the Maryland Proton Alliance at UM SOM, will receive the award in recognition of his contributions to hyperthermic oncology, the use of heat to treat cancer. At the event, Dr. Vujaskovic will also present a lecture on the reemerging role of thermal therapy in cancer treatment.